The Patient Who Pays a Price Nobody ChargesThin moat

The final relationship is with the patient, and it is mediated so heavily that the two parties barely transact. A patient sees a list price they will generally not pay, a co-payment set by a plan design they did not negotiate, and a coverage decision made by an intermediary they have never heard of. Lilly, meanwhile, receives a net price that is far below the list — the gap created by the rebates struck for formulary placement¹.

This gap explains behaviour that otherwise looks irrational. Manufacturers raise list prices partly because rebates are calculated as a percentage of them, so a higher list can be necessary to fund a competitive rebate — producing headlines about price increases in the same period that realised prices fall. Lilly's realised price declined by double digits in a recent quarter while demand grew strongly.

The incretin era is putting real pressure on the arrangement, because these are chronic medicines for very large populations, and plans cannot absorb them at branded prices the way they absorbed drugs for smaller diseases. That pressure is what produces coverage restrictions, and ultimately what makes the cash-pay channel attractive to both Lilly and the patient.

Watch realised price and volume together. Volume growing while realised price falls is the system working as designed; both falling at once would mean the payers have decided the category costs too much, which is the outcome the root threat on pricing describes.